…JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts.
…Investment bolsters immediate capital needs for progressing clinical programs
SEATTLE, March 10, 2015 – TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.
“We believe immunotherapy is one of the most exciting new approaches to the treatment of multiple cancers and promising early clinical results suggest TapImmune’s immunotherapies could become leading T-Cell stimulating therapeutics,” said Glynn Wilson Ph.D., CEO and Chairman of TapImmune.
…Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers
January 12, 2015, Seattle WA, TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial.